Cellectar Biosciences, Inc.

Wisconsin Alumni Research Foundation

Joseph J Grudzinski

Jamey Paul Weichert

Anatoly Pinchuk

Marc Longino

Chorom Pak

Kevin Kozak

Benjamin Titz

Nathan Stehle

Robert Jeraj

Paul M Sondel

Zachary Scott Morris

Peter Carlson

Wolfgang A Tome

Reinier Hernandez

Ravi Bhasker Patel

The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor. In a non-limiting example, the radioactive phospholipid ether metal chelate or radiohalogenated phospholipid ether has the formula: wherein Rcomprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half-life of greater than 6 hours and less than 30 days, or wherein Rcomprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and Ris &#x2014;N(CH).

Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies

The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.

Phospholipid ether analogs as cancer-targeting drug vehicles

A treatment schedule for radiopharmaceuticals is developed by collecting a volumetric history of tissue uptake in identified volumes of interest using emitted-radiation scans and relating this data to a treatment-radiopharmaceutical to develop a quantitatively accurate radiation treatment schedule of delivery amounts and delivery times of the treatment-radiopharmaceutical. This data may also be used to model biological effective dose and to prepare augmenting external radiation beam treatment schedules.

Treatment planning system for radiopharmaceuticals

Growing community of inventors

Madison, WI, United States of America

Joseph J Grudzinski